Use of neoadjuvant strategies part of Dr. Steven Nurkin’s talk at NCCN 2023
- Presentation to highlight treatment for Stage 2 and 3 rectal cancers
- Treatments include chemotherapy, radiation, immunotherapy
- Looks to provide insight into latest advancements in therapy
ORLANDO, FL — Roswell Park Comprehensive Cancer Center Chief of Colorectal Surgery Steven Nurkin, MD, MS, FACS, is slated to speak at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference, happening March 31-April 2 in Orlando.
Dr. Nurkin, who is also a member of NCCN’s Guidelines Panel for Colon/Rectal/Anal Cancers, will present on “Neoadjuvant Treatment Approaches for Stage II-III Rectal Cancer” on Sunday, April 2 at 9:30 a.m. EDT.
Colorectal cancer is the third most common cancer in the United States, with estimates that about 1 in 20 people will develop the disease in their lifetime. When this cancer begins in the rectum, the last several inches of the large intestine, it is called rectal cancer.
In his presentation, Dr. Nurkin will discuss using chemotherapy, radiation, and for some patients – immunotherapy – as part of a comprehensive treatment plan.
“One advantage of this therapy is that some patients may be able to avoid surgery altogether if they achieve complete clinical response, where their tumor disappears,” says Dr. Nurkin. “I hope this talk will provide valuable insight into the latest advancements in therapy for rectal cancer and highlight potential impact on patient outcomes.”
